Magic bullets for mental disorders: The emergence of the concept of an "Antipsychotic" drug

Journal of the History of the Neurosciences

Volumn 22, Issue 1, 2013, Pages 30-46

  Moncrieff, Joanna ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

antipsychotics; history of psychopharmacology; psychiatric therapeutics; treatment specificity

Indexed keywords

NEUROLEPTIC AGENT; TRANQUILIZER;

ADVERTIZING; ARTICLE; HISTORY; HUMAN; MENTAL DISEASE; PSYCHIATRY; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA;

ADVERTISING AS TOPIC; ANTIPSYCHOTIC AGENTS; HISTORY, 20TH CENTURY; HUMANS; MENTAL DISORDERS; PSYCHIATRY; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; TRANQUILIZING AGENTS;

EID: 84872844093     PISSN: 0964704X     EISSN: 17445213     Source Type: Journal    
DOI: 10.1080/0964704X.2012.664847     Document Type: Article

References (100)

1. American Psychiatric Association (1996): Schizophrenia. Washington, DC, American Psychiatric Association.
2. Anderson S (2005): Drug regulation and the welfare state: Government, the pharmaceutical industry and the health professions in Great Britain 1940 - 1980. In: Berridge V, Loughlin K, eds., Medicine, the Market and the Mass Media. London, Routledge, pp. 192-217.
3. Anton-Stephens D (1954): Preliminary observations on the psychiatric uses of chlorpromazine(Largactil). Journal of Mental Science 100: 543-557.
4. Braslow J (1997): Mental Ills and Bodily Cures. Berkeley, CA, University of California Press.
5. Carlsson A, Lindqvist M (1963): Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica (Copenh)20: 140-144.
6. Comite Lyonnais de Recherches Therapeutiques en Psychiatrie (2000): The birth of psychopharmacotherapy: Explorations in a new world - 1952 - 1968. In: Healy D, ed., ThePsychopharmacologists, Vol. III. London, Arnold, pp. 1-53.
7. Crane GE (1956): Further studies on iproniazid phosphate. Journal of Nervous and Mental Disease 124: 322-331.
8. Davis JM (1980): Antipsychotic drugs. In: Kaplan HI, Freedman AM, Sadock BJ, eds., Comprehensive Textbook of Psychiatry. Baltimore, Williams & Wilkins, 3rd edition, pp. 2257-2289.
9. Davis JM, Cole J (1975): Antipsychotic drugs. In: Freedman DX, Dyrud, JE, eds., American Handbook of Psychiatry, Vol. 5. New York, Basic Books, 2nd edition, pp. 441-475.
10. DeGrandpre, R (2006): The Cult of Pharmacology: How America Became the world's Most Troubled Drug Culture. Durham, NC, Duke University Press.
11. Delay J, Deniker P (1952): 38 cas de psychoses triates par la cure prolongee et continue de 4560 R.P. Congrès des Médecins Aliénistes et Neurologistes de Langue Francaise 50: 503-513.
12. Delay J, Deniker P (1955): Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. International Record of Medicine and General Practice Clinics 168: 318-326.
13. Delay J, Deniker P (1956): Chlorpromazine and neuroleptic treatments in psychiatry. Journal of Clinical and Experimental Psychopathology 17: 19-24.
14. Delay J, Deniker P, Green A, Mordret M (1957): Excito-motor syndrome provoked by neuroleptic drugs. Presse Medicale 65: 1771-1774.
15. Delay J, Deniker P, Harl JM(1952): Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP). Annales Medico- Psychologiques (Paris) 110: 112-117.
16. Denham J (1965): Clinical use of the phenothiazines. In: Marks J, Pare CMB, eds., The Scientific Basis of Drug Therapy in Psychiatry: Proceedings of a Symposium Held at St. Bartholomew's Hospital, London. London, Pergamon Press, pp. 56-61.
17. Denham J, Carrick DJ (1960): Therapeutic importance of extrapyramidal phenomena evoked by a new phenothiazine. American Journal of Psychiatry 116: 927-928.
18. Deniker P (1956): Psychophysiologic aspects of the new chemotherapeutic drugs in psychiatry: Some practical features of neuroleptics in order to screen new drugs. Journal of Nervous and Mental Disease 124: 371-376.
19. Deniker P (1960). Experimental neurological syndromes and the new drug therapies in psychiatry. Comprehensive Psychiatry 1: 92-102.
20. Deniker P (1970): Introduction of neuroleptic chemotherapy into psychiatry. In: Ayd F, Blackwell B, eds., Discoveries in Biological Psychiatry. Philadelphia, J B Lippincott Company, pp. 155-164.
21. Deniker P (1989): From chlorpromazine to tardive dyskinesia (brief history of the neuroleptics). Psychiatric Journal of the University of Ottawa 14: 253-259. (Pubitemid 19116301)
22. Droleptan advertisement (1980): Droleptan advertisement. British Journal of Psychiatry 136(April). Eli Lilly (2011): How Zyprexa works. Retrieved from www.zyprexa.com/schizophrenia/pages/ howzyprexaworks.aspx
23. Elkes J, Elkes C (1954): Effects of chlorpormazine on the behaviour of chronically overactive psychotic patients. British Medical Journal II: 560-565.
24. Fentazin advertisement (1975): Fentazin advertisement. British Journal of Psychiatry 126(February).
25. Flugel F (1959): Clinical and investigative aspects. In: Kline NS, ed., Psychopharmacology Frontiers: Second International Congress of Psychiatry Psychopharmacology Symposium. London, J&A Churchill Ltd., pp. 45-47.
26. Freyhan FA (1959): Clinical and investigative aspects. In: Kline NS, ed., Psychopharmacology Frontiers: Second International Congress of Psychiatry Psychopharmacology Symposium. London, J&A Churchill Ltd., pp. 7-14.
27. Gelman S (1999): Medicating Schizophrenia: A History. New Brunswick, NJ, Rutgers University Press.
28. Haase HJ (1954): Occurrence and interpretation of psychomotor parkinsonism in megaphen or largactil prolonged therapy. Nervenarzt 25: 486-492.
29. Haase HJ (1956): Definition and mode of action of the psychomotor Parkinson syndrome therapeutically induced by serpasil and largactil. Monatsschrift Psychiatrie fur Neurologie 131: 201-214.
30. Haase H-J, Janssen PAJ (1965): The Action of Neuroleptic Drugs. Chicago, Yearbook Medical Publishers.
31. Healy D (1996): The Psychopharmacologists: Interviews by David Healy (Vol. I). London, Chapman and Hall.
32. Healy D (1999): The Psychopharmacologists (Vol. II). London, Arnold.
33. Healy D (2000): The Psychopharmacologists (Vol. III). London, Arnold.
34. Healy D (2002): The Creation of Psychopharmacology. Cambridge, MA, Harvard University Press.
35. Henderson D, Gillespie RD (1962): Henderson and Gillespie's Textbook of Psychiatry. Oxford, Oxford University Press, 9th edition.
36. Himwich HE (1955): Prospects in psychopharmacology. Journal of Nervous and Mental Disease 122: 413-423.
37. Hoch P (1959): Drug therapy. In: Arieti S, ed., American Handbook of Psychiatry (Vol. II). New York, Basic Books, 1st edition, pp. 1541-1551.
38. Hollister LE (1957): Complications from the use of tranquilizing drugs. New England Journal of Medicine 257: 170-177.
39. Ilyas S, Moncrieff J (2012): Trends in prescriptions and costs of drugs for mental disorders in England, 1998 to 2010. British Journal of Psychiatry 77: 86-92.
40. Karn WN, Jr., Kasper S (1959): Pharmacologically induced Parkinson-like signs as index of the therapeutic potential. Diseases of the Nervous System 20: 119-122.
41. Kinross-Wright V (1956): Clinical application of chlorpormazine. In: Kline NS, ed., Psychopharmacology: A Symposium Organised by the Section on medical Sciences for the American Association of the Advancement of Science and the American Psychiatric Association. Washington DC, American Association for the Advancement of Science, pp. 31-38.
42. Kline NS (1956): Chemotherapy in psychiatry: Recent advances. Seminars International 5: 7-10.
43. Kline NS (1959): Psychopharmaceuticals: Effects and side effects. Bulletin of the World Health Organisation 21: 397-410.
44. Kline NS (1969): Nomenclature vs. nature. International Journal of Psychiatry 7: 292-293.
45. Laborit H, Huguenard P (1951): Artificial hibernation by pharmacodynamical and physical means. Presse Medicale 59: 1329.
46. Laborit H, Huguenard P, Alluaume R (1952): A new vegetative stabilizer; 4560 R.P. Presse Medicale 60: 206-208.
47. Largactil advertisement (1965): Largactil advertisement. British Journal of Psychiatry 111 (January): x.
48. Lehmann H (1959). Concepts, rationale and research. In: Kline NS, ed., Psychopharmacology Frontiers: Second International Congress of psychiatry Psychopharmacology Symposium. London, J & A Churchill Ltd., pp. 21-30.
49. Lehmann HE (1993): Before they called it psychopharmacology. Neuropsychopharmacology 8: 291-303. (Pubitemid 23162956)
50. Lehmann HE, Hanrahan GE (1954): Chlorpromazine: New inhibiting agent for psychomotor excitement and manic states. American Medical Association Archives of Neurology and Psychiatry 71:227-237.
51. Maas JW, Garver DL (1975): Linkage of basic neuropharmacology and clinical psychopharmacology. In: Hamburg DA, Brodie HKH, eds., American Handbook of Psychiatry (Vol. 6). New York, Basic Books, 2nd edition, pp. 427-459.
52. Malitz S, Hoch P (1966): Drug therapy: Neuroleptics and tranquilizers. In: Arieti S, ed., American Handbook of Psychiatry (Vol. III). New York, Basic Books, 2nd edition, pp. 458-476.
53. Mapp Y, Nodine JH (1962): Psychopharmacology: II. Tranquilizers and antipsychotic drugs. Psychosomatics 3: 458-463.
54. Mayer-Gross W, Slater E, Roth M (1960): Clinical Psychiatry. London, Cassell & Co., 2nd edition.
55. Mayer-Gross W, Slater E, Roth M (1969): Clinical Psychiatry. London, Bailliere Tindall, 3rd edition.
56. Melleril advertisement (1960): Melleril advertisement. Journal of Mental Science 106(April): Iii-vii. Melleril advertisement (1965): Melleril advertisement. British Journal of Psychiatry 111(February): I-vi.
57. Melleril advertisement (1970):Melleril advertisement. British Journal of Psychiatry 117(September): xii-xiii.
58. Meltzer HY, Babo WV (2009): Antipsychotic and anticholinergic drugs. In: Gelder MG, Andreasen NC, Lopez-Ibor JJ, Jr., Geddes JR, eds., New Oxford Textbook of Psychiatry. Oxford, Oxford University Press, pp. 1208-1231.
59. Meyers FH (1956): Pharmacology of chlorpormazine, reserpine and related drugs. In: Kline NS, ed., Psychopharmacology: A symposium held by the Section on Medical Sciences of the American Association for the Advancement of Science and the American Psychiatric Association. Washington DC, American Association for the Advancement of Science, pp. 131-140.
60. Moncrieff J (1999): An investigation into the precedents of modern drug treatment in psychiatry. History of Psychiatry 10: 475-490.
61. Moncrieff J (2006): Psychiatric drug promotion and the politics of neo-liberalism. British Journal of Psychiatry 188: 301-302.
62. Moncrieff J (2008a): The creation of the concept of the antidepressant: An historical analysis. Social Science and Medicine 66: 2346-2355. (Pubitemid 351608724)
63. Moncrieff J (2008b): The Myth of the Chemical Cure: A Critique of psychiatric Drug Treatment. Basingstoke, Hampshire, UK, Palgrave Macmillan.
64. Moncrieff J (2009): A critique of the dopamine hypothesis of schizophrenia and psychosis. Harvard Review of Psychiatry 17: 214-225.
65. Moncrieff J, Cohen D (2005): Rethinking models of psychotropic drug action. Psychotherapy and Psychosomatics 74: 145-153. (Pubitemid 41094845)
66. Moncrieff J, Crawford MJ (2001): British psychiatry in the 20th century - Observations from a psychiatric journal. Social Science and Medicine 53: 349-356. (Pubitemid 32479582)
67. National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group (1964): Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry 10: 246-258.
68. Neulactil advertisement (1970): Neulactil advertisement. British Journal of Psychiatry 116(February): Iii.
69. Newcomer JW, Haupt DW (2006): The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry 51: 480-491. (Pubitemid 44166336)
70. Overholser W: (1956): Has chlorpromazine inaugurated a new era in mental hospitals? Journal of Clinical and Experimental Psychopathology 17: 197-201.
71. Pellegrino ED (1979): The socio-cultural impact of twentieth century therapeutics. In: Vogel MJ, Rosenberg CE, eds., The Therapeutic Revolution. Philadelphia, PA, University of Pennsylvania Press, pp. 245-266.
72. RayWA, Chung CP, Murray KT, Hall K, Stein CM (2009): Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine 360: 225-235.
73. Redeptin advertisement (1975): Redeptin advertisement. British Journal of Psychiatry 126(June). Reserpine advertisement (1956): Reserpine advertisement. Journal of Mental Science 102 (January): V.i.
74. Roberts MHT (1973): Pharmacology of drugs of importance in psychiatry. In: Forrest A, ed., Companion to Psychiatric Studies (Vol. 1). Edinburgh, Churchill Livingstone, 1st edition, pp. 348-385.
75. Rogers A, Pilgrim D (2001): Mental Health Policy in Britain. Basingstoke, Hampshire, Palgrave Macmillan, 2nd edition.
76. Rosenberg CE (1986): Disease and social order in America: Perceptions and expectations. Milbank Quarterly 64: 34-55. (Pubitemid 17034493)
77. Rosenhan DL (1973): On being sane in insane places. Science 179: 250-258.
78. Royal College of Psychiatrists (2007): Antidepressants. London, Royal College of Psychiatrists.
79. Sainz AA (1956): Considerations on the cerebral action of Reserpine. In: Kline NS, ed., Psychopharmacology: A Symposium Held by the Section on medical Sciences of the American Association for the Advancement of Science and the American Psychiatric Association. Washington DC, American Association for the Advancement of Science, pp. 59-63. Sarwer-Foner GJ (1960): The role of neuroleptic medication in psychotherapeutic interaction. Comprehensive Psychiatry 1: 291-300.
80. Scull A (1993): The Most Solitary of Afflictions. New Haven, Yale University Press.
81. Serenace advertisement (1965): Serenace advertisement. British Journal of Psychiatry 111(January): xiii.
82. Serenace advertisement (1970): Serenace advertisement. British Journal of Psychiatry
83. (February): xv.Serenace advertisement (1975): Serenace advertisement. British Journal of Psychiatry 126(March):vi-vii.
84. Shorter E (1997): A history of Psychiatry: From the Era of the Asylum to the Age of Prozac. NewYork, John Wiley & Sons.
85. Sigwald J & Bouttier D (1953): Le chlorhydrate de cloro-3(dimethylamine-3-propyl)-10-phenothiazine en practique neuro-psychiatrique courante. Annals Medicale 54: 150-184.
86. Smith Kline & French Laboratories (1955): Chlorpormazine and Mental Health: Proceedings Held Under the Auspices of Smith Kline & French Laboratories. Philadelphia, Lea &Febiger.
87. Smythies JR (1973): Drug treatment of schizophrenia. In: Forrest A, ed., Companion to PsychiatricStudies (Vol. 2). Edinburgh, Churchill Livingstone, pp. 250-288.
88. Snyder SH (1980): Basic science of psychopharmacology. In: Kaplan HI, Freedman AM, Sadock BJ, eds., Comprehensive Textbook of Psychiatry. Baltimore, Williams & Wilkins, 3rd edition, pp. 154-165.
89. Spitzer RL (1976): More on pseudoscience in science and the case for psychiatric diagnosis. A critiqueof D. L. Rosenhan's "On Being Sane in Insane Places" and "The Contestual Nature ofPsychiatric Diagnosis." Archives of General Psychiatry 33: 459-470.
90. Steck H (1954): Le syndrome extra-pyramidal et di-encephalique au cours des traitments au Largactil at au Serpasil. Annales Medico-Psychologiques 112: 737-743.
91. Stelazine advertisement (1965a). Stelazine advertisement. British Journal of Psychiatry111(February): Ii.
92. Stelazine advertisement (1965b). Stelazine advertisement. British Journal of Psychiatry111(September): xiv.
93. Sussman N (2009): General principles of psychopharmacology. In: Sadock BJ, Sadock VA, Ruiz P, eds., Comprehensive Textbook of Psychiatry. Philadelphia, Wolters Kluwer/Lippincott Williams& Wilkins, 9th edition, pp. 2965-2988.
94. Swazey J (1974): Chlorpromazine in Psychiatry. Cambridge, MA, Massachusetts Institute of Technology.
95. Szasz T (1957): Some observations on the use of tranquilizing drugs. AMA Archives of Neurology and Psychiatry 77: 86-92.
96. Triperidol advertisement (1970): Triperidol advertisement. British Journal of Psychiatry 116(February): I.
97. Van Rossum JM(1966): The significance of dopamine receptor blockade for the action of neuroleptic drugs. In: Brill H, ed., Neuro-psycho-pharmacology. Amsterdam, Excerpta Medica Foundation,pp. 321-329.
98. Verdoux H, Tournier M, Begaud B (2010): Antipsychotic prescribing trends: A review of harmacoepidemiologicalstudies. Acta Psychiatrica Scandinavia 121: 4-10.
99. Whitaker R (2002): Mad in America. Cambridge, MA, Perseus Publishing.
100. Wilson M (1993): DSM-III and the transformation of American psychiatry: A history. AmericanJournal of Psychiatry 150: 399-410.